Is there a concentration-effect relationship for sulphonylureas?

Clinical Pharmacokinetics

Volumn 34, Issue 3, 1998, Pages 181-188

  Melander, Arne ^a,d   Donnelly, Richard ^b   Rydberg, Tony ^a,c  

^a Network for Pharmacoepidemiology Foundation   (Sweden)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c The Pharmacies in Skane   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; FOOD INTAKE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS;

EID: 0031939514     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834030-00001     Document Type: Review

References (28)

1. Lebovitz H, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester: Wiley & Sons Ltd. 1997: 817-40
2. + channels. Annu Rev Pharmacol Toxicol 1993; 33: 597-637
3. Sundaresen P, Lykos D, Daher A, et al. Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics. Clin Exp Pharmacol Physiol 1947; 24: 333-5
4. Draeger E. Clinical profile of glimepiride. Diab Res Clin Pract 1995; 28 Suppl.: 139-46
5. Bijlstra PJ, Lutterman JA, Russel FGM, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996; 39: 1083-6
6. Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-5
7. Rydberg T, Jönsson A, Røder M, et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026-30
8. Wahlin-Boll E, Almér L-O, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982; 7: 363-72
9. Groop LC, Groop P-H, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671-8
10. Arnqvist HJ, Karlberg BE, Melander A. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann Clin Res 1983; 15 Suppl. 37: 21-5
11. Groop LC, Luzi L, Melander A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320-8
12. Bitzén P-O, Melander A, Scherstén B, et al. The influence of glipizide on early insulin release and glucose disposal before and after diet regulation in diabetic patients with different degrees of hyperglycaemia. Eur J Clin Pharmacol 1988; 35: 31-7
13. Markovic TP, Furler SM, Jenkins AB, et al. Importance of early insulin concentrations on prandial glycaemic responses and thermogenesis in non-insulin-dependent diabetes mellitus. Diabetic Med 1995; 12: 523-30
14. Rydberg T, Wahlin-Boll E, Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr 1991; 564: 223-33
15. Rydberg T, Jönsson A, Karlsson M-O, et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997; 43: 373-81
16. Rydberg T, Jönsson A, Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther 1995; 20: 283-95
17. Jönsson A, Rydberg T, Sterner G, et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function Eur J Clin Pharmacol. In press
18. Silins RA, Butcher MA, Marlin GE. Improved effect of tolbutamide when given before food in patients with long-term therapy [letter]. Br J Clin Pharmacol 1984; 18: 647-8
19. Sartor G, Lundquist I, Melander A, et al. Improved effect of glibenclamide on administration before breakfast. Eur J Clin Pharmacol 1982; 21: 403-8
20. Wahlin-Boll E, Melander A, Sartor G, et al. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. Eur J Clin Pharmacol 1980; 18: 279-83
21. Groop L, De Fronzo R, Luzi L, et al. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet 1989 Jul 15; II: 129-30
22. Hoffman A, Fischer Y, Gilhar D, et al. The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus. Eur J Clin Pharmacol 1995; 47: 53-6
23. Melander A, Sartor G, Wahlin E, et al. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. BMJ 1978; 1: 142-4
24. Sartor G, Melander A, Schersten B, et al. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 1980; 18: 17-22
25. Donnelly R, Meredith PA, Elliott HL. The description and prediction of antihypertensive drug response: an individualized approach. Br J Clin Pharmacol 1991; 31: 627-34
26. Karam JH, Sanz N, Salamon E, et al. Selective unresponsiveness of pancreatic B cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986; 35: 1314-20
27. Wählin-Boll E, Sartor G, Melander A, et al. Impaired effect of sulphonylurea following increased dosage. Eur J Clin Pharmacol 1982; 22: 21-5
28. Stenman S, Melander A, Groop P-H, et al. What is the benefit of increasing the sulphonylurea dosage? Ann Intern Med 1993 Feb; 118: 169-72